维莫德吉诱导的脱发：皮肤镜和共聚焦显微镜评估
Vismodegib-Induced Alopecia: Trichoscopic and Confocal Microscopy Evaluation.
作者信息
Cantelli Mariateresa, Cappello Milena, Vastarella Maria, Patrì Angela, Scalvenzi Massimiliano, Fabbrocini Gabriella
机构信息
Department of Clinical Medicine and Surgery, Section of Dermatology, University of Naples Federico II, Napoli, Italy.
出版信息
Skin Appendage Disord. 2020 Nov;6(6):384-388. doi: 10.1159/000510121. Epub 2020 Sep 9.
INTRODUCTION
Vismodegib is the first-in-class inhibitor of the sonic hedgehog pathway useful in the treatment of locally advanced or metastatic basal cell carcinoma (BCC) that is not amenable to surgery and radiation therapy. Common adverse events of vismodegib, probably mechanism related, include alopecia (58%) as a reversible side effect.
CASE PRESENTATION
We report 2 cases of patients receiving vismodegib for the treatment of locally advanced BCCs that developed alopecia during treatment and describe clinical, dermoscopic, and reflectance confocal microscopy (RCM) features of this adverse event.
CONCLUSION
Alopecia is one of the most distressing adverse events leading to vismodegib discontinuations. To our knowledge, these are the first descriptions of RCM dermoscopy in vismodegib-induced alopecia. Trichoscopy and confocal microscopy are essential to monitoring vismodegib hair loss and the response to the treatment.
引言
维莫德吉是首个用于治疗不宜手术和放射治疗的局部晚期或转移性基底细胞癌（BCC）的音猬因子信号通路抑制剂。维莫德吉常见的、可能与机制相关的不良事件包括脱发（58%），这是一种可逆的副作用。
病例报告
我们报告了2例接受维莫德吉治疗局部晚期基底细胞癌的患者，他们在治疗期间出现了脱发，并描述了这一不良事件的临床、皮肤镜和反射式共聚焦显微镜（RCM）特征。
结论
脱发是导致停用维莫德吉的最令人苦恼的不良事件之一。据我们所知，这些是关于RCM皮肤镜检查在维莫德吉所致脱发中的首次描述。毛发镜检查和共聚焦显微镜检查对于监测维莫德吉引起的脱发及治疗反应至关重要。
Zotero 插件